Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05652686
Title A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Phanes Therapeutics
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.